top of page
The Professional Network for Healthcare Experts
FDA expands Olumiant approval to adolescents with severe alopecia areata
The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata.
nuaxia
Sep 281 min read
CHMP Recommends Olumiant for Adolescents with Severe Alopecia Areata in the EU
Positive opinion based on Phase 3 BRAVE-AA-PEDS trial supports first-in-class JAK inhibitor therapy for young patients with profound hair loss.
nuaxia
Feb 271 min read
bottom of page